Innovation Pharmaceuticals Inc (IPIX)

[ROMAD Diver]

I briefly mentioned a few days ago what I thought is missing here--understanding of what we have (and overunderstanding in some cases). We have a couple of First-In-Class products leading our company. How do we truly measure their successes and failures? What existing data do we have to compare our products with to properly define success and failure? Easy answers for Kevetrin may be something like tumor stabilization, tumor shrinkage, and/or restaging of the patients. Well, I dont see it being that simple because of the extremely broad range of...stuff...that p53 actually is responsible for (most we still don't know or fully understand). In this trial we may discover that K is great against cancer, but it may come at a cost that isn't worth it. We don't know because this is so new. As for those who study p53, they have a better idea of the true power K might hold, and they stay away from it because of what ifs. Genotoxicity is only a smal part of the equation.

After all that I have read on p53 and this company, I am here because of Kevetrin and believe it has it's place in the world. I knowingly take the risk that certain really nasty things might develop at an accelerated rates because of K. But maybe they don't! Too many unknowns in First-In-Classes for many to take a leap of faith on, but not me. I like high risk ventures.

My two cents...